Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 14Thoracic 6Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 463Neoplasms, Plasma Cell 81Lymphoma 75Leukemia 51Lymphoma, Non-Hodgkin 49Leukemia, Lymphocytic, Chronic, B-Cell 45Myelodysplastic Syndromes 43Immunoglobulin Light-chain Amyloidosis 42Leukemia, Myeloid, Acute 39Hodgkin Disease 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Neoplasms 32Hematologic Neoplasms 31Breast Neoplasms 31Myeloproliferative Disorders 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 29Monoclonal Gammopathy of Undetermined Significance 28Smoldering Multiple Myeloma 25Lymphoma, Mantle-Cell 25Lymphoma, B-Cell, Marginal Zone 24Recurrence 23Burkitt Lymphoma 21Amyloidosis 21Prostatic Neoplasms 20Lymphoma, T-Cell, Cutaneous 20Lymphoma, Large-Cell, Immunoblastic 19Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 19Waldenstrom Macroglobulinemia 18Sezary Syndrome 18

Interventions

Hematologic Tests 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Dyspnea × Plasma cell × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡